Hospira Inflectra tick
September 12, 2013
HOSPIRA has confirmed that
the European Union has approved
its Inflectra (infliximab) biosimilar
for Remicade, which is the first
biosimilar monoclonal antibody
therapy authorised in the EU.
The company said the drug
will be launched “at the earliest
opportunity taking into account any
relevant patent protection”.
Sales of J&J’s Remicade, which is
used to treat a range of conditions
including rheumatoid arthritis,
were worth over $2 billion in
Europe last year, with Hospira
estimating that the launch of
biosimilar monoclonal products in
the EU will deliver savings of up to
€20.4 billion (A$29b) by 2020.
Hospira holds the rights to
Inflectra in a number of countries
including the US, Canada, Australia
and New Zealand, under a 2009
agreement with South Korean
biopharmaceutical company
Celltrion.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Sep 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Sep 13
